Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of May 21, 2026, LGND trades at $217.75 with a market cap of $4.17B and a P/E ratio of 27.80. LGND moved +4.88% today. Year to date, LGND is +13.39%; over the trailing twelve months it is +107.54%. Its 52-week range spans $93.58 to $247.38. Analyst consensus is strong buy with an average price target of $279.71. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded LGND stock?
Recent politician trading activity in LGND includes disclosures from Gilbert Cisneros and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
LGND Key Metrics
Key financial metrics for LGND
Metric
Value
Price
$217.75
Market Cap
$4.17B
P/E Ratio
27.80
EPS
$7.90
Dividend Yield
0.08%
52-Week High
$247.38
52-Week Low
$93.58
Volume
0
Avg Volume
0
Revenue (TTM)
$274.48M
Net Income
$153.56M
Gross Margin
0.00%
Congressional Trades in LGND
Gilbert Cisneros purchase LGND on Jan 15, 2026 (amount: $15.00K).
Gilbert Cisneros purchase LGND on Jan 5, 2026 (amount: $15.00K).
Recent politician trading activity in LGND includes disclosures from Gilbert Cisneros and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in LGND?
Yes. Rallies tracks politician and congressional stock disclosures for LGND, including reported purchases, sales, dates, owners, and trade amounts when available.
Is LGND research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.
